PIPELINE
Genagon has an exciting program with a unique ADC which targets tumors and the tumor microenvironment. The target accumulates only on the surface of cells within the tumor and is rapidly internalized, enabling targeting with low risk of side-effects.
TARGETING NEW BIOLOGY
Exploring a novel protein for drug delivery in untreatable solid tumors
Genagon has characterized a novel transmembrane protein target ubiquitously expressed on epithelial cancers as well as on tumor stroma cells. The dynamics of the target protein translocation between cell compartments enables a rapid internalization of drug conjugated antibodies resulting in efficient killing of not only tumor cells but also of harmful tumor-associated stroma cells. This creates a unique and unprecedented opportunity to fight a large variety of solid tumors with the same cost-effective drug.
The tumor microenvironment is a complex structure of cancer cells recruiting innate immune cells to protect the tumor and promote its growth. Disrupting this interplay is a potent tool for cancer therapies. Genagon pioneered a way to simultaneously target cancer cells and detrimental macrophages and innate immune cells.
Killing of not only tumor cells and harmful tumor-associated macrophages directly pave the way for complete tumor clearance with a significantly decreased risk for future relapses.
The ADC program – opportunity for a first-in-class drug
Antibody-Drug Conjugates are highly potent biopharmaceutical drugs built by attaching a small cytotoxic molecule or another therapeutic agent to an antibody. Using the antibody’s property to target a specific antigen only found on target cells, ADCs deliver the highly potent drugs with a very high specificity to target cells whilst sparing healthy cells. In this way ADCs maximize the efficacy and minimize systemic exposure with associated side effects. ADCs combine the two major advantages of chemotherapy and treatment with biologicals: they are cost-effective and at the same time highly specific with high efficacy and minor systemic effects. Genagon is exploring several ADC assets including the lead drug candidate, GEN201.
THERAPEUTIC PROGRAMS
Pipeline
PIPELINE
Genagon Therapeutic Programs
THERAPEUTIC PROGRAM
Triple negative breast cancer (TNBC)
ADC candidate specialized to treat triple negative breast cancer (TNBC) patients, an indication with a high unmet clinical need. These patients do not benefit from conventional breast cancer treatment due to their tumors lacking the target proteins Estrogen, Progesterone and HER2. TNB is the most aggressive form of breast cancer and is highly prone to metastasis. GEN202 is a fully human monoclonal antibody conjugated to a cytotoxic drug optimized to eradicate both the target positive breast cancer cells as well as stromal cells within the tumor mass and potential metastases.
THERAPEUTIC PROGRAM
Solid Tumors
Solid tumors in general are classified as diverse cancers depending on their localization in the body, but recent advances in molecular understanding have revealed that it is the mechanistical drivers and not the location of a tumor that defines them. A large subgroup of solid tumor constitutes adenocarcinomas. Several of adenocarcinomas have the highest mortality of all cancers, often due to lack of specific symptoms and lack of good diagnostic markers, leading to late diagnosis. Genagon has identified a specific subgroup of patients with solid tumors expressing the specified target. These include patients from Non-small cell lung cancer (NSCLC), Head & Neck and Esophagus, Gastric and GI-tract cancer.
THERAPEUTIC PROGRAM
Lymphomas
Lymphomas are a group of blood cancers forming solid tumors within lymph nodes. The cellular origin varies greatly and over 60 types have been identified. Genagon has identified specific subgroups of patients expressing the specified target within both Hodgkin’s lymphoma and Non-Hodgkin’s lymphoma.
OPPORTUNITY IN CANCER
Checkpoint blockade-targeting therapies in the adaptive immune system like the PD-1/PDL1 and CTLA-4 demonstrate the power of antibody treatments for targeting cancer. These therapies broke new in cancer therapy by efficiently modulating the adaptive immune system to attack the cancer. However, the blockade was not enough to completely eradicate tumors. Macrophages’ ability to block infiltration of other immune cells is a major roadblock for PD1/PD-L1 clinical efficacy today.
High infiltration of macrophages in tumors has resulted in unfavorable prognosis and ineffective treatment outcomes in past studies. Targeting macrophages in cancer treatment shows promise as a tool in combination with other checkpoint blockades to eradicate tumors that we fail to treat today.
GENAGON THERAPEUTIC PROGRAMS
Therapeutic ProgramTN Breast Cancer
ADC candidate specialized to treat triple negative breast cancer (TNBC) patients, an indication with a high unmeet clinical need. These patients do not benefit of conventional breast cancer treatment due to their lack of the target proteins; Estrogen, Progesterone and HER2. It is the most aggressive form of breast cancer and are highly prone to metastasis. GEN-201 is a fully human monoclonal antibody conjugated to a cytotoxic drug optimized to eradicate both the target positive breast cancer cells and the stromal cells within the tumor mass and their metastases.
Therapeutic ProgramSolid Tumors - Lymphoma and Carcinoma
Solid tumors are in general classified as different cancers depending on their physical localizations, but modern advancements in molecular understanding have reviled that there is the mechanistical drivers of each tumor that define them. Genagon has identified a specific subgroup of patients with solid tumors expressing the specified target biology. These include patients from Non-small cell lung cancer (NSCLC), Head & Neck and Esophagus, Gastric and GI-tract cancer.
Therapeutic ProgramChronic Lung Disorders
Lymphomas are a group of blood cancers originating from and forming solid tumors within the lymph nodes. The cellular origin and causation vary greatly and over 60 types have been identified. Genagon has identified specific subgroups of patients expressing the specified target biology within both Hodgkin’s lymphoma and Non-Hodgkin’s lymphoma.
Integer enim neque volutpat ac tincidunt vitae semper quis. Fermentum dui faucibus in ornare quam viverra orci. Nulla posuere sollicitudin aliquam ultrices sagittis orci. Sed viverra ipsum nunc aliquet bibendum enim facilisis gravida. Pellentesque adipiscing commodo elit at imperdiet dui. Consectetur a erat nam at lectus urna duis convallis convallis.
Amet luctus venenatis lectus magna fringilla. Quam quisque id diam vel quam elementum pulvinar etiam non. Commodo ullamcorper a lacus vestibulum sed arcu non odio. Massa massa ultricies mi quis hendrerit dolor magna eget est. Volutpat consequat mauris nunc congue nisi.
Integer enim neque volutpat ac tincidunt vitae semper quis. Fermentum dui faucibus in ornare quam viverra orci. Nulla posuere sollicitudin aliquam ultrices sagittis orci. Sed viverra ipsum nunc aliquet bibendum enim facilisis gravida. Pellentesque adipiscing commodo elit at imperdiet dui. Consectetur a erat nam at lectus urna duis convallis convallis.
Amet luctus venenatis lectus magna fringilla. Quam quisque id diam vel quam elementum pulvinar etiam non. Commodo ullamcorper a lacus vestibulum sed arcu non odio. Massa massa ultricies mi quis hendrerit dolor magna eget est. Volutpat consequat mauris nunc congue nisi.
LEARN MORELorem ipsum dolor sit amet
Information about area 1
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
Information about area 2
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
Information about area 3
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.
Information about area 4
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.